Difference between revisions of "Inotuzumab ozogamicin (Besponsa)"
Jump to navigation
Jump to search
m (→References) |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
| Line 27: | Line 27: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Antibody-drug conjugates]] | [[Category:Antibody-drug conjugates]] | ||
[[Category:Anti-CD22 antibodies]] | [[Category:Anti-CD22 antibodies]] | ||
Revision as of 19:50, 27 February 2020
General information
Class/mechanism: Antibody targeting CD22, conjugated with a cytotoxic, antitumor antibiotic (calicheamicin). Inotuzumab demonstrates a dose-dependent cytotoxicity both in vitro and in vivo. [1][2][3][4]
Route: IV
Extravasation: No information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 8/17/2017: FDA approved "for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)."
Also known as
- Code name: CMC-544
- Brand name: Besponsa